The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice

Trials on cardiovascular and renal outcomes in patients with type 2 diabetes have consistently demonstrated that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of diabetic kidney disease (DKD) progression. However, their renal protective mechanisms have yet to be completely unders...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zi, Murakoshi, Maki, Ichikawa, Saki, Koshida, Takeo, Adachi, Eri, Suzuki, Chigure, Ueda, Seiji, Gohda, Tomohito, Suzuki, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714078/
https://www.ncbi.nlm.nih.gov/pubmed/33098615
http://dx.doi.org/10.1002/2211-5463.13014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714078/
https://www.ncbi.nlm.nih.gov/pubmed/33098615
http://dx.doi.org/10.1002/2211-5463.13014

Ejemplares similares